Item 7.01 Regulation FD Disclosure.

On November 25, 2019, Aquestive Therapeutics, Inc. (the "Company") issued a press release announcing that the Company received FDA approval for Exservan™(riluzole) Oral Film. A copy of such press release is attached as Exhibit 99.1 to this report and incorporated into this Item 7.01 by reference.

The information in this Item 7.01 (including Exhibit 99.1) is being furnished pursuant to Item 7.01 and shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in any such filing.

Item 9.01 Financial Statements and Exhibits





(d) Exhibits.

Exhibit
Number     Description

  99.1     Press Release, dated November 25, 2019, announcing the Company's
           receipt of FDA approval for Exservan™ (riluzile) Oral Film.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses